文献速递核素与放射性配体治疗肿瘤 PET/CT

肝癌树脂微球放射栓塞后90Y分布的定量影像生物标志物

Quantitative Imaging Biomarkers for 90Y Distribution on Bremsstrahlung SPECT After Resin-Based Radioembolization.
PubMed 文献 · J Nucl Med · 2019-01-17

本研究回顾性纳入38例肝癌患者(HCC 23例,非HCC 15例)共40次树脂微球TARE治疗,分析术前MRI/CT影像特征与术后Bremsstrahlung SPECT上90Y分布的相关性。结果显示HCC患者基线强化肿瘤体积百分比(ETV%)与SPECT肿瘤-正常肝比值(TNR)显著相关(P<0.001),非HCC患者亦相关(P=0.039)。ETV%变化与TNR的相关性仅在HCC中显著(P=0.039),非HCC中不显著(P=0.886)。

要点

  • 基线ETV%与HCC患者90Y SPECT TNR显著相关(P<0.001)。
  • ETV%变化与TNR的相关性仅在HCC中显著(P=0.039),非HCC不显著。
  • Child-Pugh B级患者非肿瘤肝组织90Y沉积显著多于A级(P=0.021)。

核心结论

  • 术前MRI/CT的ETV%可作为定量影像生物标志物预测HCC和非HCC患者TARE术后90Y在SPECT上的分布。
  • 90Y优先摄取与肿瘤缓解的关系仅在HCC中得到验证。

研究设计与样本

  • 回顾性研究,经机构审查委员会批准,纳入38例肝癌患者(HCC 23例,非HCC 15例),共40次树脂微球TARE治疗(2012年8月至2018年1月)。
  • 术前行动态增强MRI或CT,术后2小时内行Bremsstrahlung SPECT,进行多模态图像配准后量化90Y分布。

主要发现

  • HCC患者基线ETV%与SPECT TNR显著正相关(P<0.001),非HCC患者亦相关(P=0.039)。
  • 23例患者25次治疗有TARE后1-4月随访影像评估疗效,HCC中ETV%变化与TNR显著相关(P=0.039),非HCC中不显著(P=0.886)。
  • Child-Pugh B级患者非肿瘤肝组织90Y沉积显著多于Child-Pugh A级(P=0.021)。

关键数值与推荐

  • HCC患者基线ETV%与SPECT TNR相关P<0.001。
  • 非HCC患者ETV%与TNR相关P=0.039。
  • HCC中ETV%变化与TNR相关P=0.039,非HCC中P=0.886。
  • Child-Pugh B级与A级非肿瘤肝组织90Y沉积差异P=0.021。

临床怎么用

  • 可利用术前MRI/CT测量的ETV%预判TARE术后90Y在肿瘤与正常肝组织的分布。
  • 对HCC患者,ETV%变化与90Y优先摄取相关,或有助于预测肿瘤缓解。
  • Child-Pugh B级患者非肿瘤肝组织90Y沉积更多,需关注肝功能对分布的影响。

局限性

  • 回顾性研究,样本量有限(38例患者,40次治疗)。
  • 疗效评估仅23例患者25次治疗有随访影像。
  • 90Y优先摄取与肿瘤缓解的关系仅在HCC中得到验证,非HCC未验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our purpose was to identify baseline imaging features in patients with liver cancer that correlate with 90Y distribution on postprocedural SPECT and predict tumor response to transarterial radioembolization (TARE). Methods: This retrospective study was approved by the institutional review board and included 38 patients with hepatocellular carcinoma (HCC) (n = 23; 18/23 men; mean age, 62.39 ± 8.62 y; 34 dominant tumors) and non-HCC hepatic malignancies (n = 15; 9/15 men; mean age, 61.13 ± 11.51 y; 24 dominant tumors) who underwent 40 resin-based TARE treatments (August 2012 to January 2018). Multiphasic contrast-enhanced MRI or CT was obtained before and Bremsstrahlung SPECT within 2 h after TARE. Total tumor volume (cm3) and enhancing tumor volume (ETV [cm3] and % of total tumor volume), and total and enhancing tumor burden (%), were volumetrically assessed on baseline imaging. Up to 2 dominant tumors per treated lobe were analyzed. After multimodal image registration of baseline imaging and SPECT/CT, 90Y distribution was quantified on SPECT as tumor-to-normal-liver ratio (TNR). Response was assessed according to RECIST1.1 and quantitative European Association for the Study of the Liver criteria. Clinical parameters were also assessed. Statistical tests included Mann-Whitney U, Pearson correlation, and linear regression. Results: In HCC patients, high baseline ETV% significantly correlated with high TNR on SPECT, demonstrating greater 90Y uptake in the tumor relative to the liver parenchyma (P < 0.001). In non-HCC patients, a correlation between ETV% and TNR was observed as well (P = 0.039). Follow-up imaging for response assessments within 1-4 mo after TARE was available for 23 patients with 25 treatments. The change of ETV% significantly correlated with TNR in HCC (P = 0.039) but not in non-HCC patients (P = 0.886). Additionally, Child-Pugh class B patients demonstrated significantly more 90Y deposition in nontumorous liver than Child-Pugh A patients (P = 0.021). Conclusion: This study identified ETV% as a quantifiable imaging biomarker on preprocedural MRI and CT to predict 90Y distribution on postprocedural SPECT in HCC and non-HCC. However, the relationship between the preferential uptake of 90Y to the tumor and tumor response after radioembolization could be validated only for HCC.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Schobert I, Chapiro J, Nezami N, et al. Quantitative Imaging Biomarkers for 90Y Distribution on Bremsstrahlung SPECT After Resin-Based Radioembolization. J Nucl Med. 2019. PMID: 30655331. doi:10.2967/jnumed.118.219691

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。